Allergenic Extract Data Search Should Be Broadened, FDA Advisory Committee Says
This article was originally published in The Pink Sheet Daily
Executive Summary
In addition to medical publications and adverse event reports, FDA should utilize a search engine such as Google "to cast a wider net" over available sources of safety and efficacy data on the roughly 1,200 Category IIIA allergenic products it is seeking to reclassify, the committee says.
You may also be interested in...
Allergenic Product New Data To Be Considered By Cmte. In Reclassification Review
Data generated since 1983 reclassification panel report will aid FDA’s Allergenic Products Advisory Committee in determining agency’s position on categories for allergenic products on April 7. Reclassification panel’s recommendations in 1983 to classify most allergenic products as Category I were never implemented by FDA.
Italy Leads European Push Into Conditional Reimbursement
Italy claims to have pushed farther into managed entry agreements than other European countries with strong clawback provisions on new drugs – particularly cancer drugs – if they don't work as well as their manufacturers claim. The financial clawbacks are supported by extensive outcome data collection across the country's twenty regions.
Changes To The NHS: How Can Pharma Best Position Itself?
The U.K.’s Health and Social Care Bill was introduced into Parliament on Jan. 19, offering a new commercial landscape best navigated by pharma through bolstered relationships with general practitioners.